Skip to main content

Peer Review reports

From: MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis

Original Submission
6 Nov 2018 Submitted Original manuscript
23 Feb 2019 Reviewed Reviewer Report - Irene Cortese
25 Mar 2019 Author responded Author comments - Antonio Uccelli
Resubmission - Version 2
25 Mar 2019 Submitted Manuscript version 2
Publishing
3 Apr 2019 Editorially accepted
9 May 2019 Article published 10.1186/s13063-019-3346-z

You can find further information about peer review here.

Back to article page